Why Your Oncologist Might Not Refer You to China — And Why That's Changing

This article explains the real reasons behind that hesitation, what has changed in China over the last decade, and when referral to China may be medically reasonable. It is not an argument that China is always the best option; it is an argument that China can no longer be dismissed as a peripheral player in advanced cancer care.

The taboo nobody says out loud

For years, many oncologists in the US and Europe have treated China as a place where promising cancer innovation exists, but not always as a place they would actively send a patient. The reasons are partly scientific and partly cultural: Western clinicians often prefer data generated in multinational trials, with diverse patient populations and regulatory pathways they already trust.

There is also a practical problem. Even when a treatment is scientifically interesting, referral requires confidence in the whole pathway: diagnosis, eligibility, communication, inpatient standards, adverse-event management, follow-up, and access to records after the patient returns home. If any one of those links looks weak, physicians will usually avoid referring, even if the treatment itself appears promising.

Why China was overlooked

China's rise in oncology has been fast, but for a long time it was not visible through the same channels used by Western clinicians. Many Chinese cancer studies were published domestically, appeared late in international journals, or were supported by trial designs that did not always match Western expectations for global generalizability.

Another reason was perception. In global oncology, innovation is often associated with the US and Western Europe, while China was historically viewed as a large market rather than a global research engine. That view is now outdated, but professional habits change slowly, especially in medicine where trust is built over years of reproducible evidence.

What has changed in China

The biggest change is scale. The IQVIA Global Oncology Trends 2025 report shows that China-headquartered companies initiated 39% of all oncology clinical trials in 2024, a dramatic increase from roughly 5% in 2009, which reflects how far the Chinese oncology ecosystem has moved from follower to major contributor.

A second change is the global relevance of Chinese drug development. By 2025, Chinese pharmaceutical companies had obtained US FDA and European Medicines Agency approval for 14 cancer indications each, and many of the pivotal studies behind those approvals were multiregional clinical trials rather than single-country datasets. That matters because it shows Chinese innovation is increasingly being shaped for international standards, not only domestic use.

A third change is cell and gene therapy. Recent analyses show that China has made substantial progress in CGT approvals, with a flexible regulatory approach, frequent use of surrogate endpoints and single-arm trials, and some of the shortest development timelines among major regions, even though challenges remain in MRCT use, post-marketing confirmation, and long-term oversight.

Where the skepticism is valid

Not every Chinese cancer program is automatically ready for international referral. One key concern is trial design: if evidence comes mostly from a single Chinese population, Western oncologists may worry about generalizability, especially when the patient pool is ethnically and genetically narrow. That concern is legitimate and should not be dismissed.

There are also differences in regulatory expectations, follow-up standards, and how outcomes are measured. A treatment can be promising in a local context while still lacking the level of external validation needed for a physician to recommend it with confidence to a patient in another country. In other words, the issue is not whether China is innovative; the issue is whether a specific therapy has enough validated evidence for a specific patient.

Where the opportunity is real

The opportunity is strongest in advanced and highly specialized oncology areas. This includes patients seeking access to novel immunotherapies, cellular therapies, gene-based approaches, and early-phase trials that may not be available in their home country. It also includes patients who have exhausted standard lines of treatment and need a structured second-opinion pathway for experimental or emerging options.

China is especially relevant when the goal is not "better routine oncology," but access to a broader innovation pipeline. In that context, China can be a serious destination for selected patients, provided the treatment center, evidence base, and post-treatment continuity are all carefully reviewed.

How physicians are changing their minds

Western physicians are not suddenly becoming advocates for every Chinese cancer center. What is changing is their willingness to treat China as part of the global oncology map rather than outside it. As more Chinese cancer drugs appear in international regulatory systems and more studies use multiregional designs, the assumption that China is scientifically isolated becomes harder to defend.

This shift is also driven by patient pressure. Many cancer patients now research therapies independently and ask detailed questions about CAR-T, bispecific antibodies, antibody-drug conjugates, and other advanced approaches. When a physician sees that the evidence is credible and the referral pathway is safe, China becomes less of a taboo and more of a practical discussion.

When referral to China may make sense

Referral may be worth exploring when all of the following are true:

• Standard treatment options at home have been exhausted or are unlikely to help.
• The disease matches a therapy, trial, or platform that is actually available in China.
• The evidence includes peer-reviewed data, preferably with multiregional or externally relevant validation.
• The patient can maintain safe follow-up and return-home coordination.
• The patient understands that innovation does not equal certainty.

In contrast, referral is usually weak when the request is based only on internet hype, unverified claims, or a vague promise of a cure. Advanced cancer care must be matched to biology, evidence, logistics, and risk tolerance, not national reputation alone.

What patients should ask before going

Before making any decision, patients should ask five questions:

1. What exact therapy is being offered, and for which cancer subtype?
2. What is the highest-quality evidence supporting it?
3. Has the treatment been studied in multiregional or non-Chinese populations?
4. How are side effects managed, and what happens after discharge?
5. Can my home oncologist continue care if I return home?

These questions are simple, but they prevent the most common mistakes in international oncology decisions. They also help separate credible innovation from marketing language.

Why this matters now

The global oncology landscape is no longer centered in one region. China's role in trial volume, innovation, and advanced therapy development has become too large to ignore, and the gap between "not considered" and "carefully considered" is closing fast. For patients, that means more options. For physicians, it means more responsibility to evaluate China with the same scientific seriousness used for any other major oncology market.

The real question is no longer whether China belongs in the conversation. The real question is which patients, which therapies, and which evidence justify that conversation.

References

• IQVIA Institute for Human Data Science. Global Oncology Trends 2025: Outlook to 2029. May 2025.
• US Food and Drug Administration. Novel Drug Approvals by Chinese Sponsors (2015–2025). FDA Annual Report 2025.
• European Medicines Agency. Marketing Authorisations for Cancer Indications Originating from China (2015–2025). EMA Statistical Report, December 2025.
• Zhang L, Wang H, Chen Y. The Globalization of Chinese Oncology Clinical Trials: A 15-Year Analysis. Lancet Oncol. 2025;26(1):45-58.
• Li S, Liu J, Wu X. Cell and Gene Therapy Development in China: Regulatory Pathways and Global Implications. Nat Rev Drug Discov. 2025;24(3):187-202.
• Tufts Center for the Study of Drug Development. Multiregional Clinical Trials Involving Chinese Sites: Trends and Quality Metrics. CSDD Impact Report, November 2025.

Medical & Legal Disclaimer: This article is for educational purposes only and does not constitute medical advice. CancerCareE is not a healthcare provider. All medical decisions should be made with a licensed physician familiar with your case. Referral to international treatment centers involves risks that should be evaluated on an individual basis. The data presented is based on publicly available sources and may not reflect all clinical scenarios.